Print ISSN: 0027-1446

Online ISSN: 2309-6217

Keywords : Lipid profile

Effect of Ginkgo biloba on lipid profile in hypertensive patients on Valsartan monotherapy

Annals of the College of Medicine, Mosul, 2018, Volume 40, Issue 2, Pages 29-33
DOI: 10.33899/mmed.2018.160002

Aim: The study was conducted to evaluate the effects of Ginkgo biloba as an add on therapy to Valsartan monotherapy in hypertensive patients on lipid profile.
Patients and methods: The study was done in private clinics in Mosul City, during a period of sixth months from 15 October 2017 to 15 April 2018. The total number of patients enrolled in the study was 50 hypertensive patients using Valsartan monotherapy of both sexes. The patients were administered Ginkgo biloba 80 mg twice daily and followed for 2 months duration. Their lipid profile was determined at baseline level and after 2 months from administration of Ginkgo biloba.
Results: Treatment with Ginkgo biloba showed a significant reduction in serum total cholesterol and triglycerides, while LDL, VLDL, HDL, and AI showed no significant changes.
Conclusion: This study revealed that Ginkgo biloba could be regarded as a natural and relatively safe drug in reducing total cholesterol and triglycerides in hypertensive patients.

Effects of Bee Propolis on Blood Pressure Record and Certain Biochemical Parameter in Healthy Volunteers

Annals of the College of Medicine, Mosul, 2018, Volume 40, Issue 1, Pages 20-26
DOI: 10.33899/mmed.2018.159191

Objectives: To evaluate the effect of encapsulated bee propolis supplementation 500 mg twice daily for 2 months on blood pressure record, fasting serum glucose, lipid profile and serum uric acid in otherwise healthy volunteers in comparison to controls.
Design: The study was conducted from October 2017 to April 2018, subjects included in the study was healthy non-obese from different areas in Mosul city, so as the control.
Subjects and methods: Forty apparently healthy subjects (Sixteen male and twenty–four female) were included in this study. Blood pressure (BP) were recorded, body weight and body mass index (BMI) were calculated, then a blood sample was taken with assay of fasting serum glucose (FSG), lipid profile {Total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL –C), while serum low density lipoprotein (LDL –C), very low density lipoprotein (VLDL-C) and atherogenic index (AI)} were calculated by using certain equations and serum uric acid (SUA), was measured for both the intervention and the control groups.
After 2 months of supplementation with encapsulated bee propolis 500 mg twice daily, the BP, body weight, BMI, LDL-C, VLDL-C and AI were calculated and FSG, TC, TG, HDL and SUA were measured for the intervention group. All data were presented as means± standard deviation (SD) of mean. Independed t –test of two mean was used. Dependent t – test of two mean was applied for the differences in the intervention group (before and after). Chi square test of independence was used for categorial variables. P–value≤0.05 was considered statistically significant.
Results: Initially, at the start of the study, there was insignificant difference between the interventions and the control groups with regard age, sex, weight, BMI, systolic and diastolic BP, serum TC, HDL- C, LDL –C, AI and SUA, with a significant differences in FSG, TG, and VLDL. By comparison before and after supplementation in the intervention groups, there was a significant decrease in the systolic and diastolic BP record, FSG, TC, TG, LDL –C, AI, SUA, with a significant increase in body weight and HDL –C.
Conclusion: Bee propolis supplementation at a dose of 500 mg twice daily for 2 months carries a beneficial effects on BP record, FSG, lipid profile, and SUA, which should be taken in preventive medicine, since hyperglycemia, hyperlipidemia and hyperureciemia, contributed to the development of atherosclerosis, cardiovascular and cerebrovascular diseases.

Body mass index and some biochemical parameters among valproate treated male epileptic patients

Imad A. Thanoon; Othman A. Pachachi

Annals of the College of Medicine, Mosul, 2011, Volume 37, Issue 1, Pages 114-121
DOI: 10.33899/mmed.2011.35782

Objective: To assess the effect of continuous valproate monotherapy (VPA) on body mass index (BMI), serum leptin, malondialdehyde (MDA) and lipid profile in male epileptic children and adult patients in comparison to healthy male controls.
Subjects, materials and methods: A case-control study design was adopted. Samples from 44 male patients (22 less than 18 years old, and 22 over than 18 years old), with primary generalized epilepsy, on continuous VPA monotherapy, for at least six months before participation in the study, were collected over the period from October 2009 to March 2010. Forty-four apparently healthy male volunteers (22 less than 18 years old, and 22 over than 18 years old) without previous history of epilepsy were recruited as controls. Serum levels of leptin, and lipid profile indices were estimated using commercially available kits and a manually prepared reagent for MDA assay. (BMI) was calculated as weight in kilograms divided by the squared height in meters.
Results: The results revealed that epileptic children and epileptic adults receiving continuous VPA monotherapy had a significantly higher BMI (p<0.001), serum leptin, serum MDA and atherogenic index (AI) and a significantly lower (p<0.001) serum high density lipoprotein cholesterol (HDL-c) as compared to their matched control subjects. The results also revealed insignificant difference in serum total cholesterol (TC), triglycerides (TGs) and low density lipoprotein cholesterol (LDL-c) between epileptic children and epileptic adults on VPA and their matched control subjects. Serum leptin was positively correlated with body mass index standard deviation score (BMI SDS) of epileptic children (r=0.542; P<0.001) and duration of using VPA (r=0.215; P<0.001) in epileptic children. The results showed insignificant difference in serum TC, TGs and LDL-c between epileptic adults on VPA and control subjects. This study also revealed that the increase in serum leptin was significantly higher (p<0.001) in epileptic adults receiving continuous VPA monotherapy than in epileptic children.
Conclusion: Continuous VPA monotherapy was associated with higher BMI and serum leptin and an increase in the oxidative stress marker MDA in both male epileptic children and adults. There was no effect of VPA use on lipid profile indices in both epileptic children and adults except significant decrease in serum HDL-c and significant increase in AI.

Keywords: Valproate, male epileptic children and adult, BMI, leptin, malondialdehyde, lipid profile

C-reactive protein and lipid profile among depot- medroxyprogesterone acetate injections users

Wahda B. Al-Youzbaki

Annals of the College of Medicine, Mosul, 2011, Volume 37, Issue 1, Pages 48-56
DOI: 10.33899/mmed.2011.34639

Objective: To study the effect of depot-medroxyprogesterone acetate (DMPA) injections on C-reactive protein (CRP) and lipid profile and to find the predictors (body weight, body mass index (BMI), blood pressure (BP) and lipid profile) that significantly predict the risk of cardiovascular disease (CVD) among DMPA injections users.
Method: A prospective cohort study was performed during the period from March 2009 to March 2010 included thirty apparently healthy married women, their age ranged between 20-35 years, who were attending Al-Batool and Al-Khansa Family Planning Centers in Mosul and started (for the first time) to use DMPA injections (150 mg medroxyprogesterone acetate), called "Depo-Provera" as contraceptive. These (DMPA users group) were compared to another 30 healthy married women who did not use any hormonal contraceptives (non users group). Both groups were followed for one year, during which blood samples were obtained from both groups, before starting to use DMPA, after 6 months and after 12 months. Sera were used for the estimation of the biochemical studied parameters using commercial kits except serum low density lipoprotein (LDL) and atherogenic index (AI) which were calculated by special equations.
Results: DMPA injections caused a non significant increase in body weight but a significant increase in BMI after 12 months. There was a significant increase in the mean diastolic blood pressure (DBP) of DMPA users according to the duration of use. The DMPA caused non significant changes in the CRP levels. There was a significant increase in serum triglycerides (TG) after 6 months of DMPA uses with respect to the duration of use. But there were non significant changes in mean serum total cholesterol (TC), high density lipoprotein (HDL), LDL and AI. Among all variables that were studied, only body weight and BMI showed a significant positive correlations with CRP. Using a stepwise multiple regression analysis, it was found that the predictors that significantly predict the risk of CVD among DMPA users were AI, DBP and TG.
Conclusion: This study found that there is a significant positive association between CRP and CVD risk factors in DMPA injections users as contraceptive. Furthermore AI, DBP and TG were found to be significant predictors for the risk of CVD among DMPA users. This study confirmed the safety of DMPA use as contraceptive medication, but that special care should be directed for patients with CVD and other patients who were more sensitive to the harmful effects of lipid in the blood.

Key words: Depot-medroxyprogesterone acetate, CRP, lipid profile.

Measurement of lipid profile parameters in hypertensivepatients using atenolol or captopril

Mohammed Khalid Al. Hamo; Rawaa Khazal Jaber; Ahmed Yahya Dallal Bashi

Annals of the College of Medicine, Mosul, 2010, Volume 36, Issue 1, Pages 41-48
DOI: 10.33899/mmed.2010.8924

Objectives: To study the effects of atenolol and captopril on lipid profile parameters including total cholesterol (TC), triglycerides (TG), High density lipoprotein cholesterol (HDL-c), Low density lipoprotein cholesterol (LDL-c) and atherogenic index (AI) in serum. Moreover to compare the effects of these drugs on the above parameters with each other.Patients and Methods: One hundred hypertensive patients were involved in this study which were divided into two groups each of 50 patients. Patients in the first group were on atenolol and the patients in the second group were on captopril. All of the cases of hypertension were of the primary type (essential) as the patients were diagnosed by specialist physicians. The patients included were not chronically using any other drugs, nor having family history of hyperlipidemia, and not suffering from any other chronic disease. The ages of the patients in the first group ranged from 35-74 years with a mean of 55±5.02 years, while the ages of the second group ranged from 36-80 years with a mean of 57±6.0 years. Another group of 50 normal individuals participated in this study as a control group, with ages ranged from 35-72 years with a mean of 53±4.4 years. Results: The results of this study showed that serum TG and AI were significantly higher in atenolol using group in comparison with the control group, while serum HDL-c concentration was significantly lower. Whereas, the remaining lipid profile parameters studied were not significantly different from the control group. Serum LDL-c concentration was significantly low in captopril using group compared with the control group whereas the remaining lipid parameters studied were not significantly changed in this group. Further analysis of the results of the present study indicated significant decreases of serum TG and AI in captopril using group in comparison with Atenolol using group. Whereas, serum HDL-c concentration was significantly higher in captopril using group. Conclusion: The overall analysis of the lipid profile parameters studied might suggest that atenolol has certain undesirable effects on these parameters while captopril has less undesirable effects. This might indicate that captopril seems to be more suitable antihypertensive agent than atenolol for patients with lipid profile abnormalities.Keywords: Serum, lipid profile, triglyceride, total cholesterol, HDL-c, LDL-c, atherogenic index, hypertension.

Effect of amlodipine on serum lipid profilein hypertensive patients

Rami M. A. Al-Hayali; Ashraf H. Ahmed

Annals of the College of Medicine, Mosul, 2009, Volume 35, Issue 1, Pages 8-12
DOI: 10.33899/mmed.2009.8897

ABSTRACTObjectives: To assess the effect of amlodipine, as monotherapy, in hypertensive patients, on serum lipid profile, as assessed by serum cholesterol, serum triglyceride, high density lipoprotein cholesterol (HDLC), and low density lipoprotein cholesterol (LDLC).Subjects and methods: Thirty three hypertensive patients were included in the study, 25 of them were males and 8 were females. Serum cholesterol, triglyceride, HDLC and LDLC were measured before and after 2 months of starting treatment with amlodipine.Results: No significant difference could be found between the pre and post treatment levels of all measured parameters.Conclusion: Treatment with amlodipine does not produce deleterious effect on lipid profile, so it may be a suitable therapy in a hypertensive patient with underlying hyperlipidaemia.